Formulation and Specifications: Tablets: 2.5mg, 5mg, 10mg
Indications: Adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or highly differentiated) progressive pancreatic neuroendocrine tumors; adult patients with unresectable, locally advanced or metastatic, well-differentiated, progressive non-functional neuroendocrine tumors of gastrointestinal or pulmonary origin.
Key points for rational drug use:
1. Common adverse reactions must be noted during drug administration, including stomatitis, rash, fatigue, diarrhea, infection, nausea, decreased appetite, anemia, taste disturbance, peripheral edema, hyperglycemia, and headache.
2. Non-infectious pneumonia is a class effect of rapamycin derivatives (including this product). Contraindicated in persons with hypersensitivity to the active ingredient, other rapamycin derivatives, or any of the excipients in this product. Manifestations of allergic reactions observed in patients using everolimus and other rapamycin derivatives include, but are not limited to: dyspnea, flushing, chest pain, or angioedema (e.g., airway or tongue swelling with or without respiratory insufficiency).
3. Patients on concomitant use of angiotensin-converting enzyme inhibitors may be at increased risk of angioedema.
4. Live vaccines such as influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccine should be avoided during treatment with this product, and close contact with persons who have received live vaccines should be avoided.
5. Routine monitoring of everolimus whole blood trough concentrations should be performed in all patients. The mortality rate and the incidence of serious adverse reactions leading to termination of therapy are significantly higher in elderly patients ≥65 years of age on the drug. Therefore, the use of everolimus in elderly patients must be monitored for the occurrence of adverse reactions and the dose of the drug should be adjusted in a timely manner.
6. Combined use of potent CYP3A4 or P-glycoprotein inhibitors and potent inducers of CYP3A4 should be avoided.